biotech / news / / Devdiscourse
A U.S. jury finds Takeda Pharmaceutical liable for causing about $885 million in damages.
A U.S. jury found Takeda liable for $885 million for delaying generic Amitiza via anticompetitive practices.
KEY POINTS
- The awarded damages could automatically triple under federal antitrust law, potentially reaching $2.47 billion.
- This is the first jury verdict holding a pharmaceutical company liable for pay-for-delay since the 2013 Supreme Court ruling.
- Takeda will revise its previous fiscal year financial statements to reflect possible litigation provisions.
- The settlement between Takeda, Sucampo, and Par delayed generic Amitiza by six years, per plaintiffs.
COMPANIES
Summarized by Newsio from Devdiscourse. How we summarize →